erdafitinib,cetrelimab
janssen
['cetrelimab', 'erdafitinib', 'norse', 'muc ,(-much)']
dr. siefer-radtke presented the updated results of the ph2 norse study evaluating erdafitinib-cetrelimab vs. erdafitinib alone in fgfr-alt muc cis-ineligible pts in the 1st line. the addition of cetrelimab appeared (ph2 preliminary data) to improve orr, cr, pfs and os. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer